Gilead, Merck Spar Over Hepatitis C $1,000-Pill Royalties

  • Merck demands $3 billion in royalties to license two patents
  • Jury in California must decide whether Merck patents are valid

Gilead Sciences Inc., which pioneered a cure for hepatitis C, is trying to fend off a demand by Merck & Co. for more than $3 billion in a patent dispute over the liver disease treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.